Tags

Type your tag names separated by a space and hit enter

Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment.
Dig Liver Dis 2010; 42(5):352-8DL

Abstract

BACKGROUND

The usefulness of celiac disease-related serology in monitoring patients on a gluten-free diet has been debated.

AIM

To describe serologic changes over time and assess whether serology tests can predict compliance with the gluten-free diet.

METHODS

Sera obtained at baseline and every 3 months thereafter for 1 year in 82 adult celiac disease patients were assayed for: (1) IgA antigliadin, (2) IgA anti-tissue transglutaminase, (3) IgA endomysial, (4) IgA, and (5) IgG anti-deamidated gliadin peptides, (6) dual detection of IgA and IgG anti-deamidated gliadin peptides, (7) a single assay for IgA and IgG of both anti-deamidated gliadin peptide and anti-tissue transglutaminase, and (8) IgA antiactin antibodies.

RESULTS

At 3 months after diagnosis, most antibody assays significant decrease in mean concentrations (p<0.0001) and the percentage of positive samples (p<0.0001) with further improvement in subsequent determinations. Strictly adherents had significantly lower concentrations of antibodies (p<0.01 to p<0.00001) and smaller proportion of positive samples for IgA endomysial, IgA antiactin antibodies and IgA antigliadin (15.6%, 17.4% and 23.9%, respectively) than partially compliant. At 1 year, IgA endomysial (p<0.02), IgA antiactin antibodies (p<0.05) and anti-tissue transglutaminase (p<0.02) predicted the degree of compliance.

CONCLUSIONS

Gluten-free diet treatment produced rapid and significant qualitative and quantitative changes in celiac disease-related antibodies which may be useful for monitoring dietary compliance.

Authors+Show Affiliations

Small Bowel Section, Department of Medicine, Dr. C. Bonorino Udaondo Gastroenterology Hospital, Buenos Aires, Argentina.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

19679520

Citation

Sugai, Emilia, et al. "Dynamics of Celiac Disease-specific Serology After Initiation of a Gluten-free Diet and Use in the Assessment of Compliance With Treatment." Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 42, no. 5, 2010, pp. 352-8.
Sugai E, Nachman F, Váquez H, et al. Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment. Dig Liver Dis. 2010;42(5):352-8.
Sugai, E., Nachman, F., Váquez, H., González, A., Andrenacci, P., Czech, A., ... Bai, J. C. (2010). Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 42(5), pp. 352-8. doi:10.1016/j.dld.2009.07.011.
Sugai E, et al. Dynamics of Celiac Disease-specific Serology After Initiation of a Gluten-free Diet and Use in the Assessment of Compliance With Treatment. Dig Liver Dis. 2010;42(5):352-8. PubMed PMID: 19679520.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Dynamics of celiac disease-specific serology after initiation of a gluten-free diet and use in the assessment of compliance with treatment. AU - Sugai,Emilia, AU - Nachman,Fabio, AU - Váquez,Horacio, AU - González,Andrea, AU - Andrenacci,Paola, AU - Czech,Andrea, AU - Niveloni,Sonia, AU - Mazure,Roberto, AU - Smecuol,Edgardo, AU - Cabanne,Ana, AU - Mauriño,Eduardo, AU - Bai,Julio Cesar, Y1 - 2009/08/12/ PY - 2008/11/29/received PY - 2009/06/24/revised PY - 2009/07/13/accepted PY - 2009/8/15/entrez PY - 2009/8/15/pubmed PY - 2010/8/10/medline SP - 352 EP - 8 JF - Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver JO - Dig Liver Dis VL - 42 IS - 5 N2 - BACKGROUND: The usefulness of celiac disease-related serology in monitoring patients on a gluten-free diet has been debated. AIM: To describe serologic changes over time and assess whether serology tests can predict compliance with the gluten-free diet. METHODS: Sera obtained at baseline and every 3 months thereafter for 1 year in 82 adult celiac disease patients were assayed for: (1) IgA antigliadin, (2) IgA anti-tissue transglutaminase, (3) IgA endomysial, (4) IgA, and (5) IgG anti-deamidated gliadin peptides, (6) dual detection of IgA and IgG anti-deamidated gliadin peptides, (7) a single assay for IgA and IgG of both anti-deamidated gliadin peptide and anti-tissue transglutaminase, and (8) IgA antiactin antibodies. RESULTS: At 3 months after diagnosis, most antibody assays significant decrease in mean concentrations (p<0.0001) and the percentage of positive samples (p<0.0001) with further improvement in subsequent determinations. Strictly adherents had significantly lower concentrations of antibodies (p<0.01 to p<0.00001) and smaller proportion of positive samples for IgA endomysial, IgA antiactin antibodies and IgA antigliadin (15.6%, 17.4% and 23.9%, respectively) than partially compliant. At 1 year, IgA endomysial (p<0.02), IgA antiactin antibodies (p<0.05) and anti-tissue transglutaminase (p<0.02) predicted the degree of compliance. CONCLUSIONS: Gluten-free diet treatment produced rapid and significant qualitative and quantitative changes in celiac disease-related antibodies which may be useful for monitoring dietary compliance. SN - 1878-3562 UR - https://www.unboundmedicine.com/medline/citation/19679520/Dynamics_of_celiac_disease_specific_serology_after_initiation_of_a_gluten_free_diet_and_use_in_the_assessment_of_compliance_with_treatment_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S1590-8658(09)00301-6 DB - PRIME DP - Unbound Medicine ER -